Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
News|Articles|March 31, 2026
The Psychiatric Pipeline in Review: Quarter 1, 2026
Author(s)Leah Kuntz
Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.
Advertisement
Advertisement
The first quarter of 2026 had several prominent developments in the psychiatric treatment pipeline. Here, learn more about what percentage of that news was positive vs negative, what disease states were most prominently featured, and what treatments you should keep an eye on.
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Advertisement
Advertisement